10 Einträge gefunden

1. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

   1. Kolberg-Liedtke, Cornelia
   2. Feuerhake, Friedrich
   3. Garke, Madlen
   4. Christgen, Matthias
   5. Kates, Ronald
   6. Grischke, Eva Maria
   7. Forstbauer, Helmut

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer

   1. Nitz, Ulrike A
   2. Gluz, Oleg
   3. Kümmel, Sherko
   4. Christgen, Matthias
   5. Braun, Michael
   6. Aktas, Bahriye
   7. Lüdtke-Heckenkamp, Kerstin

   2022 - Forschungsinformationssystem des UKE
3. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

   1. Huebner, Hanna
   2. Häberle, Lothar
   3. Müller, Volkmar
   4. Schrader, Iris
   5. Lorenz, Ralf
   6. Forstbauer, Helmut
   7. Fink, Visnja

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

   1. Graeser, Monika
   2. Harbeck, Nadia
   3. Gluz, Oleg
   4. Würstlein, Rachel
   5. Zu Eulenburg, Christine
   6. Schumacher, Claudia
   7. Grischke, Eva-Maria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials: Combined analysis from the WSG ADAPT subtrials

   1. Graeser, Monika
   2. Schrading, Simone
   3. Gluz, Oleg
   4. Strobel, Kevin
   5. Würstlein, Rachel
   6. Kümmel, Sherko
   7. Schumacher, Claudia

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

   1. Graeser, Monika
   2. Feuerhake, Friedrich
   3. Gluz, Oleg
   4. Volk, Valery
   5. Hauptmann, Michael
   6. Jozwiak, Katarzyna
   7. Christgen, Matthias

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment:A Phase 3 Randomized Clinical Trial

   1. Friedl, Thomas W P
   2. Fehm, Tanja
   3. Müller, Volkmar
   4. Lichtenegger, Werner
   5. Blohmer, Jens
   6. Lorenz, Ralf
   7. Forstbauer, Helmut

   2021 - Forschungsinformationssystem des UKE
8. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial

   1. de Gregorio, Amelie
   2. Häberle, Lothar
   3. Fasching, Peter A
   4. Müller, Volkmar
   5. Schrader, Iris
   6. Lorenz, Ralf
   7. Forstbauer, Helmut

   2020 - Forschungsinformationssystem des UKE
9. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial

   1. Jueckstock, Julia
   2. Rack, Brigitte
   3. Friedl, Thomas W P
   4. Scholz, Christoph
   5. Steidl, Julia
   6. Trapp, Elisabeth
   7. Tesch, Hans

   2016 - Forschungsinformationssystem des UKE - frei zugänglich
10. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).

    1. Loibl, Sibylle
    2. Müller, Volkmar
    3. von Minckwitz, Gunter
    4. Conrad, Bettina
    5. Koehne, Claus-Henning
    6. Kremers, Stephan
    7. Forstbauer, Helmut

    2011 - Forschungsinformationssystem des UKE